PSMA-Val-Cit-PAB-MMAE

Overview

PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA , with Monomethyl auristatin E (MMAE) ( HY-15162 ) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA , thereby being delivered into PSMA -expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B , releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity ( IC 50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > PSMA | Products > Signaling Pathways > Microtubule/Tubulin | Products > Signaling Pathways > Reactive Oxygen Species (ROS)

Product Information

• Catalog No.: HY-141860
• CAS No.: 2748039-79-2
• Molecular Formula: C114H165ClN20O26
• Molecular Weight: 2267.10
• Purity: 99.52%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source